GSK response to SFO Statement
Deutsche Grundstuckautionen AG
€9.25
15:40 19/04/24
Issued: 22 February 2019, London UK - LSE Announcement
GSK response to SFO Statement
In reference to the announcement issued by the Serious Fraud Office ("SFO") today, GlaxoSmithKline plc (LSE/NYSE: GSK) is pleased that the SFO have closed their investigation and concluded that no further action is required.
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.
GSK enquiries: | |||
UK Media enquiries: | Simon Steel | +44 (0) 20 8047 5502 | (London) |
Tim Foley | +44 (0) 20 8047 5502 | (London) | |
Analyst/Investor enquiries: | Sarah Elton-Farr | +44 (0) 208 047 5194 | (London) |
Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
Cautionary statements regarding forward-looking statements
| |
Registered in England & Wales: No. 3888792 |
|
| |
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS |
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.